Search

Your search keyword '"Abraham, Renny"' showing total 291 results
Start Over Author "Abraham, Renny"
291 results on '"Abraham, Renny"'

1. Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy

Author

Nirogi, Ramakrishna, Shinde, Anil, Goyal, Vinod Kumar, Ravula, Jyothsna, Benade, Vijay, Jetta, Satish, Pandey, Santosh Kumar, Subramanian, Ramkumar, Chowdary Palacharla, Veera Raghava, Mohammed, Abdul Rasheed, Abraham, Renny, Dogiparti, Dhanunjay Kumar, Kalaikadhiban, Ilayaraja, Jayarajan, Pradeep, Jasti, Venkat, and Bogan, Richard K.

Published
2024
Full Text
View/download PDF

2. Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling

Author

Nirogi, Ramakrishna, Grandhi, Venkata Ramalingayya, Medapati, Rajeshbabu, Ganuga, Narender, Abraham, Renny, Thentu, Jagadeesh Babu, Palacharla, Veera Raghava Chowdary, Petlu, Surendra, Srirangavaram, Maheshwari, Subramanian, Ramkumar, Ravella, Srinivasa Rao, Gagginapally, Shankar Reddy, Benade, Vijay, Jayarajan, Pradeep, and Mohammed, Abdul Rasheed

Published
2023
Full Text
View/download PDF

3. Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

Author

Nirogi, Ramakrishna, Abraham, Renny, Jayarajan, Pradeep, Goura, Venkatesh, Kallepalli, Rajesh, Medapati, Rajesh babu, Tadiparthi, Jayaprakash, Goyal, Vinod kumar, Pandey, Santosh kumar, Subramanian, Ramkumar, Petlu, Surendra, Thentu, Jagadeesh Babu, Palacharla, Veera Raghava Chowdary, Gagginapally, Shankar Reddy, Mohammed, Abdul Rasheed, and Jasti, Venkat

Published
2022
Full Text
View/download PDF

5. Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design

Author

Nirogi, Ramakrishna, primary, Abraham, Renny, additional, Ravula, Jyothsna, additional, Jetta, Satish, additional, Benade, Vijay, additional, Shinde, Anil K, additional, Rasheed, Mohammed Abdul, additional, Badange, Rajesh Kumar, additional, Goyal, Vinod Kumar, additional, Palacharla, Veera Raghava Chowdary, additional, Subramanian, Ramkumar, additional, and Jayarajan, Pradeep, additional

Published
2023
Full Text
View/download PDF

6. 5‐HT1A Receptor Agonist, SUVN‐N9503012 for the Treatment of Dementia and Associated Neuropsychiatric Disorders

Author

Abraham, Renny, primary, Petlu, Surendra, additional, Thentu, Jagadeesh Babu, additional, Grandhi, Venkata Ramalingayya, additional, Raya, Anji Reddy, additional, Ganuga, Narender, additional, Medapati, Rajesh Babu, additional, Subramanian, Ramkumar, additional, Rasheed, Mohammed Abdul, additional, and Nirogi, Ramakrishna, additional

Published
2023
Full Text
View/download PDF

13. Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer’s Disease: A Post Hoc Analysis

Author

Nirogi, Ramakrishna, primary, Jayarajan, Pradeep, additional, Abraham, Renny, additional, Tadiparthi, Jayaprakash, additional, Benade, Vijay, additional, Shinde, Anil K, additional, Rasheed, Mohammed Abdul, additional, Badange, Rajesh Kumar, additional, Goyal, Vinod Kumar, additional, Palacharla, Veera Raghava Chowdary, additional, Ravulu, Jyothsna, additional, Jetta, Satish, additional, and Subramanian, Ramkumar, additional

Published
2022
Full Text
View/download PDF

19. Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

Author

Nirogi, Ramakrishna, primary, Jayarajan, Pradeep, additional, Benade, Vijay, additional, Shinde, Anil, additional, Goyal, Vinod Kumar, additional, Jetta, Satish, additional, Ravula, Jyothsna, additional, Abraham, Renny, additional, Grandhi, Venkata Ramalingayya, additional, Subramanian, Ramkumar, additional, Pandey, Santosh Kumar, additional, Badange, Rajesh Kumar, additional, Mohammed, Abdul Rasheed, additional, Jasti, Venkat, additional, Ballard, Clive, additional, and Cummings, Jeffrey, additional

Published
2022
Full Text
View/download PDF

20. SUVN‐L3307032, A Positive Allosteric Modulator (PAM) at Muscarinic M4 Receptor for the Treatment of Neuropsychiatric Symptoms.

Author

Shinde, Anil, Guduru, Naga Sai Soma Chandra Sekhar, Das, Ankit, Bitra, Keerthi Sai, Bobbili, Hima Bindu, Mukkollu, Kavya Sree, Allu, Chaitanya Sree, Vanga, Shivani, Shyam, Radhey, Kallepalli, Rajesh, Abraham, Renny, and Nirogi, Ramakrishna

Abstract

Background: Centrally acting muscarinic acetylcholine receptor antagonists like atropine and scopolamine can induce psychosis‐like symptoms. Xanomeline, a muscarinic M1/M4 preferring agonist attenuated the effects of amphetamine (animal model for schizophrenia) in the wild‐type mice, however, such effects were absent in muscarinic M4 knockout mice. In addition, xanomeline was also found to be effective in attenuating neuropsychiatric symptoms. Thus, muscarinic M4 agents can modulate brain circuitry that is dysregulated in disease states. Method: The effects of SUVN‐L3307032 on the allosteric site of the M4 receptor were evaluated using the cell‐based reporter gene assay. The pharmacokinetic properties of SUVN‐L3307032 were studied both in rodent and non‐rodent species. SUVN‐L3307032 was assessed for its effects on amphetamine‐induced hyperlocomotion in rats at doses of 3, 10, 30, and 60 mg/kg. Preliminary toxicity studies were conducted in rats and dogs to evaluate the safety of SUVN‐L3307032. Result: SUVN‐L3307032 was found to be a positive allosteric modulator of muscarinic M4 (M4‐PAM) receptor. SUVN‐L3307032 showed good oral bioavailability in rats and dogs. It also has excellent brain penetration with an adequate free fraction in the brain. SUVN‐L3307032 showed dose‐dependent receptor occupancy at tested doses of 3, 10, 30, and 60 mg/kg. At the tested doses, SUVN‐L3307032 dose‐dependently attenuated amphetamine‐induced hyperlocomotion. The observation from the amphetamine‐induced hyperlocomotion assay correlated well with the occupancy at the allosteric site of muscarinic M4 receptors. Preliminary toxicity studies did not show any concerns for further development. SUVN‐L3307032 is being further characterized in animal models for neuropsychiatric symptoms. Conclusion: SUVN‐L3307032 could be a promising agent for the management of neuropsychiatric symptoms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. 0265 Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy

Author

Benade, Vijay, primary, Abraham, Renny, additional, Palacharla, Raghava Chowdary, additional, Thentu, Jagadeesh Babu, additional, Petlu, Surendra, additional, Mekala, Venkat Reddy, additional, Pandey, Santosh Kumar, additional, Badange, Rajesh Kumar, additional, Bojja, Kumar, additional, Reballi, Veena, additional, Achanta, Pramod Kumar, additional, Choudakari, Praveen kumar, additional, and Nirogi, Ramakrishna, additional

Published
2022
Full Text
View/download PDF

24. Samelisant (SUVN-G3031), a Histamine-3(H3) Receptor Inverse Agonist in Animal Models of Sleep Disorders (P1-1.Virtual)

Author

Nirogi, Ramakrishna, primary, Shinde, Anil, additional, Mohammed, Abdul Rasheed, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, Palacharla, Veera Raghava Chowdary, additional, Subramanian, Ramkumar, additional, Abraham, Renny, additional, Ravula, Jyothsna, additional, Jetta, Satish, additional, and Jasti, Venkat, additional

Published
2022
Full Text
View/download PDF

25. Low-dose prazosin in combination with 5-[HT.sub.6] antagonist PRX-07034 has antipsychotic effects

Author

Abraham, Renny, Nirogi, Ramakrishna, Shinde, Anil, and Irupannanavar, Shantaveer

Subjects
Research, Dosage and administration, Drug interactions -- Research, Pharmaceutical research, Prazosin -- Dosage and administration, Combination drug therapy -- Research, Drug therapy, Combination -- Research
Abstract

Introduction Schizophrenia is a debilitating disease that involves loss of rationale, disconnect from reality, and the inability to think reasonably (Baldessarini and Tarazi 2010). Schizophrenia produces positive, negative, and cognitive [...], An extensive amount of research has focused on the development of new pharmacological agents to treat schizophrenia. Varying from person to person, schizophrenia is a heterogeneous disease with symptoms of positive, negative, and cognitive deficits. PRX-07034, a 5-[hydroxytryptamine.sub.6] (5-[HT.sub.6]) receptor antagonist has been evaluated for its potential in treating obesity and cognitive deficits. This study evaluated PRX-07034 (0.1, 0.3, and 1.0 mg/kg body mass, by intraperitoneal (i.p.) injection), in combination with a low dose of prazosin (0.3 mg/kg, i.p.), for its antipsychotic potential. The research utilized a stereotypy assay, an open field test, an object recognition task, and prepulse inhibition. Dizocilpine, a non-competitive N-methyl-D-aspartate (NMDA) antagonist, was also administered in the above-mentioned assays as a psychomimetic. The combination of PRX-07034 and prazosin alleviated stereotypy and hyperlocomotor activity while enhancing memory in an object recognition task, and reversed sensory-gating deficits induced by dizocilpine. Examination of the medial prefrontal cortex revealed that a combination of PRX-07034 and prazosin reduced the dizocilpine-mediated increase of 5-HT. These results suggest that the combination of a 5-[HT.sub.6] antagonist with low doses of prazosin could have therapeutic potential in the treatment of schizophrenia. Key words: schizophrenia, open field, prepulse inhibition, stereotypy assay, object recognition task. La recherche s'est principalement concentree sur le developpement de nouveaux agents pharmacologiques visant a traiter la schizophrenie. Variable d'une personne a l'autre, la schizophrenie est une maladie heterogene qui s'accompagne de symptomes positifs, negatifs et cognitifs. Le PRX-07034, un antagoniste du recepteur de la 5-[hydroxytryptamine.sub.6] (5-[HT.sub.6]) a ete evalue dans le traitement de l'obesite et de deficits cognitifs. L'etude presente a evalue le PRX-07034 (0,1, 0,3 et 1,0 mg/kg de masse corporelle, par injection intreperitoneale (i.p.)), en combinaison avec de faibles doses de prazosine (0,3 mg/kg, i.p.), sur le plan de son pouvoir antipsychotique. Le protocole de recherche comprenait une mesure de la stereotypie, un test du champ ouvert, une tache de reconnaissance d'objet et une mesure de l'inhibition de la reaction de sursaut. La dizocilpine, un antagoniste non-competitif du recepteur du N-methyl-D-aspartate (NMDA), a aussi ete administree lors des tests mentionnes plus haut, comme agent psycho-mimetique. La combinaison de PRX-07034 et de prazosine attenuait la stereotypie et l'activite hyperlocomotrice, tout en ameliorant la memoire lors de la tache de reconnaissance d'objet et en renversant les deficits de filtrage sensoriel induits par la dizocilpine. L'examen du cortex prefrontal median a revele que la combinaison de PRX-07034 et de prazosine attenuait l'augmentation de 5-HT provoquee par la dizocilpine. Ces resultats suggerent que la combinaison d'un antagoniste du 5-[HT.sub.6] et de faibles doses de prazosine pourrait avoir un pouvoir therapeutique dans le traitement de la schizophrenie. [Traduit par la Redaction] Mots-cles: schizophrenie, champ ouvert, inhibition de la reaction de sursaut, mesure de la stereotypie, tache de reconnaissance d'un objet.

Published
2015
Full Text
View/download PDF

27. Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease

Author

Nirogi, Ramakrishna, primary, Mohammed, Abdul Rasheed, additional, Shinde, Anil Karbhari, additional, Gagginapally, Shankar Reddy, additional, Kancharla, Durga Malleshwari, additional, Ravella, Srinivasa Rao, additional, Bogaraju, Narsimha, additional, Middekadi, Vanaja Reddy, additional, Subramanian, Ramkumar, additional, Palacharla, Raghava Choudary, additional, Benade, Vijay, additional, Muddana, Nageswararao, additional, Abraham, Renny, additional, Medapati, Rajesh Babu, additional, Thentu, Jagadeesh Babu, additional, Mekala, Venkat Reddy, additional, Petlu, Surendra, additional, Lingavarapu, Bujji Babu, additional, Yarra, Sivasekhar, additional, Kagita, Narendra, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, and Jasti, Venkat, additional

Published
2021
Full Text
View/download PDF

29. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders

Author

Nirogi, Ramakrishna, primary, Grandhi, Venkata R, additional, Medapati, Rajesh B, additional, Ganuga, Narender, additional, Benade, Vijay, additional, Gandipudi, Sudhakar, additional, Manoharan, Arunkumar, additional, Abraham, Renny, additional, Jayarajan, Pradeep, additional, Bhyrapuneni, Gopinadh, additional, Shinde, Anil, additional, Badange, Rajesh K, additional, Subramanian, Ramkumar, additional, Petlu, Surendra, additional, and Jasti, Venkat, additional

Published
2021
Full Text
View/download PDF

32. SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits

Author

Abraham, Renny, primary, Goura, Venkatesh, additional, Grandhi, Venkata Ramalingayya, additional, Tadiparthi, Jayaprakash, additional, Ganuga, Narender, additional, Medapati, Rajesh Babu, additional, Muddana, Nageswara Rao, additional, Palacharla, Veera Raghava Chowdary, additional, Bhyrapuneni, Gopinadh, additional, Bojja, Kumar, additional, Mekala, Venkat Reddy, additional, Srirangavaram, Maheswari, additional, Badange, Rajesh Kumar, additional, Reballi, Veena, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, Jayarajan, Pradeep, additional, and Nirogi, Ramakrishna, additional

Published
2020
Full Text
View/download PDF

33. Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression

Author

Nirogi, Ramakrishna, primary, Mohammed, Abdul Rasheed, additional, Shinde, Anil K., additional, Ravella, Srinivasa Rao, additional, Bogaraju, Narsimha, additional, Subramanian, Ramkumar, additional, Mekala, Venkat Reddy, additional, Palacharla, Raghava Choudary, additional, Muddana, Nageswararao, additional, Thentu, Jagadeesh Babu, additional, Bhyrapuneni, Gopinadh, additional, Abraham, Renny, additional, and Jasti, Venkat, additional

Published
2020
Full Text
View/download PDF

35. P3-042: SUVN-502: A PURE 5-HT6 ANTAGONIST POTENTIATES THE EFFECTS OF DONEPEZIL OR MEMANTINE IN ANIMAL MODELS OF COGNITION, NEUROCHEMISTRY AND ELECTROPHYSIOLOGY

Author

Benade, Vijay, primary, Bhyrapuneni, Gopinadh, additional, Abraham, Renny, additional, Medapati, Rajesh Babu, additional, Daripelli, Saivishal, additional, Kamuju, Venkatesh, additional, Gandipudi, Sudhakar, additional, Tirumalasetty, Chaitanya, additional, Bojja, Kumar, additional, Manchineella, Sravanthi, additional, Nirogi, Ramakrishna, additional, and Jasti, Venkat, additional

Published
2019
Full Text
View/download PDF

38. 0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates

Author

Nirogi, Ramakrishna, primary, Bhyrapuneni, Gopinadh, additional, Abraham, Renny, additional, Subramanian, Ramkumar, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, Badange, Rajesh, additional, and Shinde, Anil, additional

Published
2019
Full Text
View/download PDF

42. P1‐075: IN‐VIVO CHARACTERIZATION OF SUVN‐I2004: AN M 1 POSITIVE ALLOSTERIC MODULATOR (PAM) IN ANIMAL MODELS OF COGNITION AND SAFETY

Author

Jayarajan, Pradeep, primary, Abraham, Renny, additional, Vuyyuru, Arun Babu, additional, Yathavakilla, Sumanth, additional, Goura, Venkatesh, additional, Daripelli, Saivishal, additional, Kamuju, Venkatesh, additional, Benade, Vijay, additional, Bhyrapuneni, Gopinadh, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, Gagginapalli, Shankar Reddy, additional, and Nirogi, Ramakrishna, additional

Published
2018
Full Text
View/download PDF

47. [P2-033]: SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE

Author

Nirogi, Ramakrishna, primary, Mudigonda, Koteshwara, additional, Ravulu, Jyothsna, additional, Bhyrapuneni, Gopinadh, additional, Benade, Vijay, additional, Muddana, Nageswara Rao, additional, Chowdary Palacharla, Veera Raghava, additional, Ajjala, Devender Reddy, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, Abraham, Renny, additional, Jayarajan, Pradeep, additional, Kambhampati, Ramasastry, additional, and Shinde, Anil K., additional

Published
2017
Full Text
View/download PDF

49. [P1-063]: SUVN-G3031, A SELECTIVE H3 RECEPTOR INVERSE AGONIST: ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS

Author

Muddana, NageswaraRao, primary, Bhyrapuneni, Gopinadh, additional, Mudigonda, Koteshwara, additional, Jayarajan, Pradeep, additional, Abraham, Renny, additional, Subramanian, Ramkumar, additional, Goyal, Vinod Kumar, additional, Pandey, Santosh Kumar, additional, Boggavarapu, Rajesh Kumar, additional, Ajjala, Devender Reddy, additional, Shinde, Anil K., additional, and Nirogi, Ramakrishna, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results